Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 22,026 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the purchase, the chief executive officer now owns 59,383 shares in the company, valued at $133,017.92. The trade was a 58.96 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Perspective Therapeutics Price Performance

CATX opened at $1.96 on Wednesday. Perspective Therapeutics, Inc. has a 1 year low of $1.90 and a 1 year high of $19.05. The company’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $6.10.

Analysts Set New Price Targets

Several brokerages have issued reports on CATX. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, March 27th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.44.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently made changes to their positions in CATX. Charles Schwab Investment Management Inc. raised its position in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares during the period. State Street Corp lifted its stake in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the period. FMR LLC increased its position in Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after buying an additional 44,174 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.